by Raynovich Rod | Sep 29, 2015 | Biopharmaceuticals
Another Rally from FED minutes…except biotech 10/8/15 … BIOTECH-Another test near 2015 lows in early AM ; choppy downtrend but look for a bottoming process as market is turning up toward close: IBB at 306 down slightly after reversal XBI down 1.7% to 63.3...
by Raynovich Rod | Sep 25, 2015 | Biopharmaceuticals
After the close 9/25…The bio-bubble has burst. XBI down 6.85%, IBB down 4.91%. Can healthcare sector recover? —– Bull Market Intact But Sentiment Has Turned Negative The severe 20%++ correction in the biotech sector is getting a lot of bearish...
by Raynovich Rod | Aug 13, 2015 | Biopharmaceuticals
Update-1 August 19… Dawg Days of August Biotech stocks remain weak with momentum plays hit the hardest. The IBB could test the recent bottom of 359 hit on reversal day last Friday and another low on August 7. There is strong support at this level so any...
by Raynovich Rod | Jul 14, 2015 | 2024 Rayno Biopharmaceuticals Portfolio
Rayno Top Winners YTD 10/12/15 Fibrocell Science (FCSC) up 69% Clovis Oncology (CLVS) up 61.6% Regeneron (REGN) up 28.4% Seattle Genetics (SGEN) up 21.3% Gilead Sciences (GILD) up 5.6% —— Rayno Top Losers YTD Biogen Idec (BIIB) down 21.5%….down again...
by Raynovich Rod | Jun 30, 2015 | 2024 Rayno Biopharmaceuticals Portfolio
Dealmaking and Fast Money Fuel Biotechs Q2 2015 Review Despite a major down trend at the end of April and the recent sell-off, the sector outperformed in Q2 of 2015. The S&P was down 1% and flat YTD. The XBI Biotech ETF continues to be the sector ETF leader up...
by Raynovich Rod | Jun 19, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update -2 … June 25… IBB off all time high of 379.97 SCOTUS opinion in favor of ACA (ObamaCare) is favorable to hospital stocks and positive for HC sector overall as we have assumed since 2010. The XLV Health Care Select SPDR ETF is up 11.25% YTD and...
by Raynovich Rod | Jun 2, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 BLUE Drops 1.96% and 1.77% After Hours 6/3 In the bubbly CAR-T world bluebird bio (BLUE) and Celgene announced a deal for for development of product candidates for B-cell maturation antigen (BMCA) utilizing bluebird bios’s gene therapy technology to...
by Raynovich Rod | Jun 1, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Indices Can’t Break Through Triple Top IBB at $365, XBI at $239 Red and green day Biotech stocks were mixed today with the major indices holding the flat line. However with all of the clinical data coming out of ASCO (American Society for Clinical...
by Raynovich Rod | May 13, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Valuations Step-Up With More Deals Prior to the acquisition of Pharmacyclics (PCYC) by Abbvie (ABBV) for $20B, the top price paid for an emerging biotech company was in the $10B range. Two additional companies among the mid-caps were acquired in prior years: Cubist...
by Raynovich Rod | Apr 20, 2015 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Big Earnings Week-AACR Data Disappoints Roller Coaster Market This will be a big week for the market with 25% of all S&P companies reporting earnings. There is a broad rally today in all major indices up over 1% with the DOW leading helped by AAPL up 2.4% on more...